Citigroup, Leerink Partners and Wells Fargo will be the bookrunners
By Devika Patel
Knoxville, Tenn., Jan. 7 – Five Prime Therapeutics, Inc. said it priced a $75.02 million public sale of stock with an $11.25 million greenshoe.
The company will sell 3.41 million common shares at $22.00 per share. The price per share is a 4.35% discount to the Feb. 5 closing share price of $23.00.
Citigroup, Leerink Partners and Wells Fargo Securities are the bookrunning managers.
Proceeds will be used for clinical development, research and pre-clinical development activities, working capital and general corporate purposes.
The clinical-stage biotechnology company is based in South San Francisco, Calif.
| Issuer: | Five Prime Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $75.02 million
|
| Greenshoe: | $11,253,000
|
| Shares: | 3.41 million
|
| Price: | $22.00
|
| Warrants: | No
|
| Bookrunners: | Citigroup, Leerink Partners and Wells Fargo Securities
|
| Co-managers: | Guggenheim Securities and Oppenheimer & Co.
|
| Pricing date: | Jan. 7
|
| Settlement date: | Jan. 12
|
| Stock exchange: | Nasdaq: FPRX
|
| Stock price: | $23.00 at close Jan. 6
|
| Market capitalization: | $474.78 million
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
